Publications
Detailed Information
The effects of psychopathology on subjective experience of side effects of antipsychotics in patients with schizophrenia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hwang, Samuel Suk-Hyun | - |
dc.contributor.author | Jung, Dong Chung | - |
dc.contributor.author | Kim, Se Hyun | - |
dc.contributor.author | Ahn, Yong Min | - |
dc.contributor.author | Kim, Yong Sik | - |
dc.date.accessioned | 2012-07-04T04:57:50Z | - |
dc.date.available | 2012-07-04T04:57:50Z | - |
dc.date.issued | 2010-03 | - |
dc.identifier.citation | INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY; Vol.25 2; 83-90 | ko_KR |
dc.identifier.issn | 0268-1315 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78401 | - |
dc.description.abstract | This study was conducted to delineate the relationship between self-reported side effects and psychopathology in schizophrenia patients. Patients with schizophrenia completed the Liverpool University Neuroleptic Side Effects Rating Scale for subjective side effects and were evaluated with the Positive and Negative Syndrome Scale for their psychopathology. Based on a series of multiple linear regression analyses, we derived a model accounting for the relationships among the specific domains of psychopathology and red herring (RH) items of the Liverpool University Neuroleptic Side Effects Rating Scale in predicting subjective side effects. The model with anxiety/depressive symptoms and RH serving as mediators between positive symptoms and side effects was found to show good fit. Positive symptoms caused mostly anxiety symptoms and tendency to report RH items, whereby resulting in over-generalized reporting of subjective side effects. However, a large proportion of variance of side effects was explained by RH, which was only partially explained by positive symptoms alone. Therefore, patients with severe levels of positive and anxiety/depressive symptoms may be prone to nocebo-like effects of antipsychotics. Studies that include acute stage patients presenting severe levels of these symptoms should not rely only on the subjective report of side effects but also apply objective measures. Int Clin Psychopharmacol 25: 83-90 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. | ko_KR |
dc.description.sponsorship | This study was supported by a grant (03-PJ10-PG13-
GD01-0002) of the Korea Health 21 R&D project, Ministry for Health, Welfare and Family Affairs, Republic of Korea. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | ko_KR |
dc.subject | nocebo effect | ko_KR |
dc.subject | psychopathology | ko_KR |
dc.subject | red herring | ko_KR |
dc.subject | schizophrenia | ko_KR |
dc.subject | Liverpool University Neuroleptic Side Effects Rating Scale | ko_KR |
dc.subject | subjective side effects | ko_KR |
dc.title | The effects of psychopathology on subjective experience of side effects of antipsychotics in patients with schizophrenia | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 정동청 | - |
dc.contributor.AlternativeAuthor | 안용민 | - |
dc.contributor.AlternativeAuthor | 김세현 | - |
dc.contributor.AlternativeAuthor | 김용식 | - |
dc.identifier.doi | 10.1097/YIC.0b013e328334e5a8 | - |
dc.citation.journaltitle | INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY | - |
dc.description.citedreference | Yilmaz Y, 2009, EUR J PAEDIATR NEURO, V13, P439, DOI 10.1016/j.ejpn.2008.08.007 | - |
dc.description.citedreference | Ahn YM, 2009, J CLIN PSYCHOPHARM, V29, P117, DOI 10.1097/JCP.0b013e31819a6995 | - |
dc.description.citedreference | Lincoln TM, 2007, SCHIZOPHRENIA BULL, V33, P1324, DOI 10.1093/schbul/sbm002 | - |
dc.description.citedreference | Reeves RR, 2007, GEN HOSP PSYCHIAT, V29, P275, DOI 10.1016/j.genhosppsych.2007.01.010 | - |
dc.description.citedreference | Benedetti F, 2006, J NEUROSCI, V26, P12014, DOI 10.1523/JNEUROSCI.2947-06.2006 | - |
dc.description.citedreference | Day JC, 2005, ARCH GEN PSYCHIAT, V62, P717 | - |
dc.description.citedreference | BENTLER PM, 1990, PSYCHOL BULL, V107, P238 | - |
dc.description.citedreference | MCLOUGHLIN C, 1992, ANAESTHESIA, V47, P202 | - |
dc.description.citedreference | HOGAN TP, 1992, PSYCHOL MED, V22, P347 | - |
dc.description.citedreference | LINDENMAYER JP, 1994, PSYCHIAT QUART, V65, P299 | - |
dc.description.citedreference | DAY JC, 1995, BRIT J PSYCHIAT, V166, P650 | - |
dc.description.citedreference | DAVIS C, 1995, J CLIN PSYCHOPHARM, V15, P347 | - |
dc.description.citedreference | Coukell AJ, 1996, CNS DRUGS, V6, P237 | - |
dc.description.citedreference | Awad AG, 2000, SCHIZOPHRENIA BULL, V26, P557 | - |
dc.description.citedreference | Cabeza IG, 2000, SCHIZOPHR RES, V41, P349 | - |
dc.description.citedreference | SIMPSON GM, 1970, ACTA PSYCHIAT SCAN S, V212, P11 | - |
dc.description.citedreference | HOGAN TP, 1983, PSYCHOL MED, V13, P177 | - |
dc.description.citedreference | LINGJAERDE O, 1987, ACTA PSYCHIATR SCA S, V334, P1 | - |
dc.description.citedreference | KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261 | - |
dc.description.citedreference | BARNES TRE, 1989, BRIT J PSYCHIAT, V154, P672 | - |
dc.description.citedreference | YI JS, 2001, J KOREAN NEUROPSYCHI, V40, P1090 | - |
dc.description.citedreference | Naber D, 2001, SCHIZOPHR RES, V50, P79 | - |
dc.description.citedreference | AHN YM, 2002, J KOREAN NUEROPSYCHI, V41, P876 | - |
dc.description.citedreference | AHN YM, 2002, J KOREAN NEUROPSYCHI, V41, P890 | - |
dc.description.citedreference | JUNG HY, 2002, J KOREAN NEUROPSYCHI, V41, P138 | - |
dc.description.citedreference | Barsky AJ, 2002, JAMA-J AM MED ASSOC, V287, P622 | - |
dc.description.citedreference | de Haan L, 2002, PSYCHOPHARMACOLOGY, V162, P24, DOI 10.1007/s00213-002-1054-x | - |
dc.description.citedreference | Kim JH, 2002, COMPR PSYCHIAT, V43, P456, DOI 10.1053/comp.2002.35908 | - |
dc.description.citedreference | Fountoulakis KN, 2003, BRIT J PSYCHIAT, V182, P81 | - |
dc.description.citedreference | Lambert TJR, 2003, HUM PSYCHOPHARM CLIN, V18, P405, DOI 10.1002/hup.495 | - |
dc.description.citedreference | Lee KH, 2003, PSYCHOPATHOLOGY, V36, P226, DOI 10.1159/000073447 | - |
dc.description.citedreference | Lehman AF, 2004, AM J PSYCHIAT, V161, P1 | - |
dc.description.citedreference | Carrick R, 2004, PSYCHOL PSYCHOTHER-T, V77, P19 | - |
dc.description.citedreference | Ritsner M, 2004, J CLIN PSYCHOPHARM, V24, P245, DOI 10.1097/01.jp.0000125684.82219.53 | - |
dc.description.citedreference | Jung HY, 2005, HUM PSYCHOPHARM CLIN, V20, P41, DOI 10.1002/hup.655 | - |
dc.description.citedreference | NABER D, 2005, ACTA PSYCHIAT SCAND, V427, P29 | - |
dc.description.citedreference | Ullman JB, 2006, J PERS ASSESS, V87, P35 | - |
dc.description.citedreference | Williamson A, 2007, NEUROTOXICOLOGY, V28, P227, DOI 10.1016/j.neuro.2006.03.009 | - |
dc.description.citedreference | Bell M, 2007, PSYCHIAT RES, V151, P37, DOI 10.1016/j.psychres.2006.04.012 | - |
dc.description.citedreference | Hwang SSH, 2009, J NERV MENT DIS, V197, P79, DOI 10.1097/NMD.0b013e318196083c | - |
dc.description.citedreference | BEBBINGTON PE, 2009, ACTA PSYCHIAT SCAN S, V438, P22 | - |
dc.description.citedreference | Voruganti LP, 2008, CURR OPIN PSYCHIATR, V21, P133 | - |
dc.description.citedreference | Foster JM, 2008, PHARMACOEPIDEM DR S, V17, P278, DOI 10.1002/pds.1533 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.